A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer

YANG Wei-xiao; SHAO Yan-xiang; HU Xu; XIONG San-chao; LIU Yang; LI Xiang

doi:10.12182/20210360203

Volume 52 Issue 2

Mar. 2021

Turn off MathJax

Article Contents

Abstract

References

JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCES) > 2021 > 52(2): 326-333. > DOI: 10.12182/20210360203

YANG Wei-xiao, SHAO Yan-xiang, HU Xu, et al. A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer[J]. Journal of Sichuan University (Medical Sciences), 2021, 52(2): 326-333. DOI: 10.12182/20210360203

Citation:

PDF (548 KB)

A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China

More Information

Corresponding author:
LI Xiang, E-mail: xiangli.87@163.com
Received Date: December 01, 2020
Revised Date: February 07, 2021
Available Online: March 21, 2021
Published Date: March 19, 2021

Abstract

Abstract

Objective To explore the best treatment plan of intravesical instillation for patients with non-muscular invasive bladder cancer (NMIBC), to explore recurrence-related clinicopathological factors after intravesical instillation, and to evaluate the value of the prognosis and prediction models currently used for NMIBC patients.
Methods Starting from 2016, patients who underwent transurethral resection of bladder tumor (TURBT) in our hospital and who received post-surgery diagnosis of having intermediate or high risks for NMIBC were enrolled in the study. They were randomly assigned to different group sat a ratio of 2∶2∶1 for receiving intravesical instillation therapy of Bacillus Calmette-Guérin (BCG) for 19 times, BCG for 15 times, and epirubicin (EPI) for 18 times. The clinicopathological data of the patients were recorded before, during and after instillation therapy, and survival curves were drawn to evaluate the effects of the three regimens, using recurrence-free survival as the endpoint. Clinicopathological data were analyzed to study the associations between various factors and post-instillation recurrence. The consistency index (c-index) was used to evaluate the predictive accuracy of the scoring model of the Spanish Urological Club for Oncological Treatment (CUETO) and the risk tables of European Organization for Research and Treatment of Cancer (EORTC).
Results A total of 93 NMIBC patients (35 in the 19-time BCG group, 37 in the 15-time BCG group, and 21 in the EPI group) were included, with a median follow-up time of 33.46 months. Twenty-two patients experienced tumor recurrence and eight, tumor progression. The survival curve showed that the BCG group had better recurrence-free survival than the EPI group (P=0.002), while the difference in recurrence-free survival between 19-time BCG and 15-time BCG groups was not statistically significant. Higher general complication rate was seen in the BCG groups compared with the EPI group (84.7% vs. 61.9%, P=0.022), but there was no grade 3-5 adverse events in any group. The c-index of CUETO scoring model and EORTC risk tables was higher than that of the prediction based solely on T stage, nuclear grade, or EAU risk stratification. In addition, the c-index in the BCG group was higher than that in the whole cohort.
Conclusion Among the subjects of this study, the recurrence rate of bladder cancer in the intravesical BCG instillation groups was lower than that of the epirubicin group. EORTC risk tables and CUETO scoring model exhibited higher predictive accuracies in BCG-treated patients than its performance for the whole NMIBC cohort.
- Bladder cancer,
- Bacillus Calmette–Guérin,
- Epirubicin,
- Intravesical instillation,
- Recurrence,
- Prognosis,
- Predictive model

FullText(HTML)

References (20)

References

[1]	MATTIUZZI C, LIPPI G. Currentcancer epidemiology. J Epidemiol Glob Health,2019,9(4): 217–222. DOI: 10.2991/jegh.k.191008.001
[2]	韩苏军, 张思维, 陈万青, 等. 中国膀胱癌发病现状及流行趋势分析. 癌症进展,2013,11(1): 89–95. DOI: 10.3969/j.issn.1672-1535.2013.01.021
[3]	BURGER M, CATTO J W F, DALBAGNI G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol,2013,63(2): 234–241. DOI: 10.1016/j.eururo.2012.07.033
[4]	KAUFMAN D S, SHIPLEY W U, FELDMAN A S. Bladder cancer. Lancet,2009,374(9685): 239–249. DOI: 10.1016/S0140-6736(09)60491-8
[5]	BABJUK M, BURGER M, COMPÉRAT E M, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and CarcinomaIn Situ) - 2019 Update. Eur Urol,2019,76(5): 639–657. DOI: 10.1016/j.eururo.2019.08.016
[6]	CHANG S S, BOORJIAN S A, CHOU R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol,2016,196(4): 1021–1029. DOI: 10.1016/j.juro.2016.06.049
[7]	SYLVESTER R J, BRAUSI M A, KIRKELS W J, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol,2010,57(5): 766–773. DOI: 10.1016/j.eururo.2009.12.024
[8]	PAN J, LIU M, ZHOU X. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with non-muscle invasive bladder cancer? An update and cumulative meta-analysis. Front Med,2014,8(2): 241–249. DOI: 10.1007/s11684-014-0328-0
[9]	FERNANDEZ-GOMEZ J, MADERO R, SOLSONA E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guérin: the CUETO scoring model. J Urol,2009,182(5): 2195–2203. DOI: 10.1016/j.juro.2009.07.016
[10]	NICHOLLS R J, ZINICOLA R, HABOUBI N. Extramural spread of rectal cancer and the AJCC cancer staging manual 8th edition, 2017. Ann Oncol,2019,30(8): 1394–1395. DOI: 10.1093/annonc/mdz147
[11]	SYLVESTER R J, VAN DER MEIJDEN A P, OOSTERLINCK W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol,2006,49(3): 466–475. DOI: 10.1016/j.eururo.2005.12.031
[12]	HARRELL F E, Jr, LEE K L, MARK D B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med,1996,15(4): 361–387. DOI: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
[13]	MORALES A, EIDINGER D, BRUCE A W. Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol,1976,116(2): 180–183. DOI: 10.1016/S0022-5347(17)58737-6
[14]	AKAZA H, KURTH K H, WILLIAMS R, et al. Intravesical chemotherapy and immunotherapy for superficial tumors basic mechanism of action and future direction. Urol Oncol,1998,4(4/5): 121–129. DOI: 10.1016/S1078-1439(99)00015-0
[15]	SMALDONE M C, GAYED B A, TOMASZEWSKI J J, et al. Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. Minerva Urol Nefrol,2009,61(2): 71–89.
[16]	SHANG P F, KWONG J, WANG Z P, et al. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev, 2011, 5: CD006885[2020-11-12]. https://doi.org/10.1002/14651858.CD006885.pub2
[17]	JÄRVINEN R, KAASINEN E, SANKILA A, et al. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol,2009,56(2): 260–265. DOI: 10.1016/j.eururo.2009.04.009
[18]	SYLVESTER R J. Maintenance Bacillus Calmette-Guérin therapy: the search for the optimum treatment schedule continues. Eur Urol,2015,68(2): 263–264. DOI: 10.1016/j.eururo.2015.03.029
[19]	HUANG Z, LIU H, WANG Y, et al. Determining optimal maintenance schedules for adjuvant intravesical Bacillus Calmette-Guérin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis. Curr Med Res Opin,2017,33(8): 1379–1387. DOI: 10.1080/03007995.2017.1326889
[20]	CAMBIER S, SYLVESTER R J, COLLETTE L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guérin. Eur Urol,2016,69(1): 60–69. DOI: 10.1016/j.eururo.2015.06.045

Relative Articles

Supplements (0)

Cited By

Get Citation

PDF

XML

Article views (2156) PDF downloads (77)

A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer

Abstract

References

Catalog

Export File

Citation

Format

Content